PBL cell: potential targeted therapies. BCMA, B-cell maturation antigen; brentuximab vedotin, anti-CD30 antibody-drug (monomethyl auristatin) conjugate; CAR-T, chimeric antigen receptor T-cell therapy; daratumumab, human IgG1 monoclonal antibody targeting the plasma cell marker CD38; IMIDs, immunomodulators including lenalidomide, thalidomide, pomalidomide. ∗Not yet evaluated.